RYTM News and Press, Rhythm Pharmaceuticals Inc. From 08/07/19

-- Both studies met primary and all key secondary endpoints with statistically significant and clinically meaningful results in reductions of weight and hunger -- -- Rhythm on track to complete rolling NDA submission to the FDA for both POMC and LEPR deficiency obesities in 4Q19 or 1Q...

Rhythm Pharmaceuticals (NASDAQ: RYTM ): Q2 GAAP EPS of -$1.24 misses by $0.36 . More news on: Rhythm Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

-- Launched Uncovering Rare Obesity to facilitate diagnosis of rare genetic disorders of obesity --   -- Announced positive opinion by EMA on Orphan Drug Designation for setmelanotide for the treatment of patients with BBS --    -- Topline data from pivot...

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending Orphan Drug designation for Rhythm Pharmaceuticals' ( RYTM -1.2% ) setmelanotide for the potential treatment of Bardet-Biedl syndrome , a rare genetic disorder characterized by obesity, visua...

BOSTON, July 29, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that the European Medicines Agencyȁ...

BOSTON, July 24, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the appointment of Stuart Arbuckle to it...

-- Uncovering Rare Obesity program may help determine underlying cause of severe obesity -- -- Program increases access to genetic testing to improve diagnosis of rare genetic disorders of obesity --  BOSTON, July 17, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:...

Fate Therapeutics (NASDAQ: FATE ) initiated with Outperform rating and $27 (32% upside) price target at Oppenheimer. Shares up  3%  premarket. More news on: RedHill Biopharma Ltd., Fate Therapeutics, Inc., Rhythm Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, ...

Aurora Cannabis (NYSE: ACB ) initiated with Neutral rating at Compass Point. Shares down a fraction premarket. More news on: Aurora Cannabis Inc., Rhythm Pharmaceuticals, Inc., Array BioPharma Inc., Healthcare stocks news, Stocks on the move, , Read more ...

BOSTON, June 19, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the election of Jennifer Good to its Boa...